Alvin Shih

Dr. Alvin Shih is an experienced physician and biopharma executive with a track record of building and leading companies that develop therapeutics addressing significant unmet medical needs.  Since 2021, he has been CEO of Catamaran Bio, a venture-backed company developing allogeneic cell therapies.  Prior to Catamaran, he was CEO of Disarm Therapeutics (acquired by Eli Lilly) and Enzyvant Therapeutics (acquired by Sumitomo).  He previously held senior leadership roles at Retrophin and Pfizer, where he was the Chief Operating Officer of the Pfizer Rare Disease Research Unit.  Dr. Shih began his career as a management consultant at McKinsey & Co. and LEK Consulting. 

He holds an MBA from the Kellogg School of Management, an MD from the University of Alabama, and completed his residency training in internal medicine at the Massachusetts General Hospital.